Rheumatoid Arthritis: Changing the Disease, Not Just the Pain
Painkillers can ease the ache of rheumatoid arthritis, but they don't stop the disease from destroying joints. The breakthrough was a completely different class of drug — the DMARDs — that actually slows or halts the underlying process. Understanding the difference between relieving symptoms and modifying disease is the key to all of rheumatology.
Rheumatoid arthritis (RA) is not the ordinary 'wear and tear' arthritis of old age. It's an autoimmune disease: the immune system mistakenly attacks the lining of the joints, causing chronic inflammation that is painful, swells the joints, and — critically — progressively destroys the cartilage and bone, leading to permanent deformity and disability. This distinction matters enormously for treatment. You could give a patient with RA all the painkillers in the world — NSAIDs, even steroids — and ease their pain, but underneath, the immune attack would grind on, quietly wrecking the joints. The great advance in treating RA was realising that you have to treat the disease itself, not just the symptoms — and that led to a whole class of drugs with a revealing name.
Symptom relief vs disease modification
DMARDs change the course of the disease; painkillers only mask it. The name says it all: DMARDs — Disease-Modifying Anti-Rheumatic Drugs. This is the crucial concept. NSAIDs and steroids are symptom-relievers: they reduce the pain and inflammation you feel, but they don't alter the underlying autoimmune disease, so the joint destruction continues underneath. DMARDs are disease-modifiers: they act on the immune process driving the arthritis, slowing or stopping the destruction of the joints, and can put the disease into remission. In other words, painkillers treat how RA feels; DMARDs treat what RA does. Because RA causes permanent, irreversible joint damage, and because that damage happens early, the modern principle is to start a DMARD as soon as RA is diagnosed — 'treat early, treat to target' — rather than waiting. Starting a DMARD promptly can prevent joint destruction that no later treatment could ever undo. NSAIDs and steroids still have a role, but only as add-on symptom control while the DMARD does the real work of protecting the joints. This shift — from merely relieving pain to actively modifying the disease — transformed the outlook for RA from inevitable disability to often-controllable illness.
The DMARD families
DMARDs fall into a few groups, which the next articles explore. The conventional (older) DMARDs are the foundation: methotrexate is by far the most important and the usual first choice (the 'anchor' drug, covered next), alongside others like sulfasalazine, hydroxychloroquine and leflunomide. They're small-molecule drugs that broadly dampen the overactive immune process, taken as tablets, and they work slowly — over weeks to months — so patience is needed and symptom-relievers bridge the gap while they take effect. Because they suppress the immune system, they all require regular monitoring (blood tests to watch the blood counts, liver and kidneys, and vigilance for infection). When conventional DMARDs aren't enough, the biologic DMARDs come in — the targeted antibodies like anti-TNF drugs that you've now met in asthma and IBD, applied here to RA — and the newer targeted synthetic DMARDs, the oral JAK inhibitors. The overall strategy is a ladder much like IBD: start with methotrexate, combine or escalate if needed, and move to biologics for disease that stays active. But the single most important idea to carry from this article isn't any drug name — it's the concept itself: in rheumatoid arthritis, treating the pain is not enough; you must modify the disease, and you must do it early.
- RA is an autoimmune disease that progressively destroys joints — not ordinary wear-and-tear arthritis.
- Painkillers (NSAIDs, steroids) relieve symptoms but DON'T stop the joint destruction.
- DMARDs (Disease-Modifying Anti-Rheumatic Drugs) act on the immune process, slowing/halting the disease.
- Start a DMARD EARLY (at diagnosis) — joint damage is permanent and happens early ('treat to target').
- Conventional DMARDs (methotrexate first) → combine/escalate → biologics; all need monitoring.
The single most important idea in rheumatology is hidden in the name DMARD: disease-MODIFYING. It captures a distinction that runs through all of medicine — the difference between treating how a disease feels and treating what it does. In rheumatoid arthritis this is not academic: painkillers can make a patient comfortable while their joints are silently destroyed forever, whereas a DMARD, started early, can preserve those joints by switching off the immune attack that damages them. This is why 'treat early' is such a mantra in RA — the damage is permanent, so every month of active disease costs joint that can never be recovered. Whenever you meet a chronic inflammatory or autoimmune disease, ask the DMARD question: is this drug just relieving symptoms, or is it actually changing the course of the disease? The two are worlds apart.
- Treating RA with painkillers alone — the joints keep being destroyed underneath.
- Delaying a DMARD after diagnosis — early damage is permanent; start promptly.
- Expecting a DMARD to work immediately — conventional DMARDs act over weeks to months.
- Forgetting that DMARDs suppress immunity and need regular monitoring.
What makes DMARDs different from painkillers in rheumatoid arthritis?
- RA is an autoimmune disease that permanently destroys joints — painkillers don't stop this.
- DMARDs modify the disease: they act on the immune process to slow/halt joint destruction.
- Start a DMARD EARLY (at diagnosis) — damage is permanent; methotrexate is the usual first choice.
- Conventional DMARDs → biologics/JAK if needed; all suppress immunity and need monitoring.
- Katzung BG. Basic & Clinical Pharmacology — NSAIDs, DMARDs & Drugs Used in Gout.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Immunosuppressants & antirheumatic drugs.
- ACR / EULAR — Rheumatoid arthritis management guidelines (treat-to-target).
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — DMARDs.
